Hims and Hers Health Inc vs TJX Companies Inc — how do they compare? Hims and Hers Health Inc trades at $30.91 (market cap $6.55B), while TJX Companies Inc trades at $138.02 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 23.3× Hims and Hers Health Inc's market cap, and TJX Companies Inc pays a 1.38% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and TJX Companies Inc for 97 Days on average.
| HIMS | TJX | |
|---|---|---|
Market Cap | $6.55B | $152.62B |
Volume | 14,842,814 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $168.41 |
52-Week Low | $14.52 | $122.84 |
Typical Hold Time | 21 Days | 97 Days |
Enterprise Value | $7.25B | $160.93B |
Dividend Yield | — | 1.38% |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.
The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.
TJX trades at $138.76, down slightly by 0.03% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals, with revenue rising to $56.36B in 2025 and net income reaching $4.86B, alongside robust profitability metrics like a 62.17% ROE. Recent quarterly earnings have consistently beaten expectations, and the firm maintains a solid balance sheet with manageable debt levels.
The outlook for TJX is positive, supported by Wall Street's strong buy consensus (84.9% buy ratings) and a $174.15 price target implying 28% upside. Key risks include competitive pressures in off-price retail and sensitivity to consumer spending trends. Investor sentiment is buoyed by earnings momentum and expansion potential, though overbought technical conditions may prompt near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →